Top Medical News
Pearl Toh, Yesterday
Achieving a stringent glycated haemoglobin (HbA1c) goal of <6.5 percent within 6 months of metformin initiation was associated with a decreased risk of cardiovascular (CV) events and mortality in real-world patients with type 2 diabetes, with a greater magnitude of HbA1c reduction being predictive of a lower outcome risk, according to a large Danish registry-based study.
The presence of nonalcoholic fatty liver disease (NAFLD) is a risk factor for arterial stiffness among postmenopausal women, independent of the presence of metabolic syndrome, a recent study has found.
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
Pearl Toh, 2 days ago
The Micra leadless transcatheter pacing system (TPS) demonstrates a high implant success rate of 99.6 percent with low major complication rate at 30 days after implantation in real-world patients, which appears to surpass its performance observed in the IDE* trial that drove its approval, according to an interim analysis of an ongoing prospective postapproval registry.
Jairia Dela Cruz, 2 days ago
Pioglitazone may effectively reduce the risk of acute coronary syndrome (ACS) following a cerebrovascular event among patients with insulin resistance (IR) but without diabetes mellitus, with the most prominent effect observed on spontaneous type 1 myocardial infarctions, according to a secondary analysis of the IRIS* trial.
2 days ago
A history of migraine headache is a predictor of increased risk of future cardiovascular (CV) events (cardiovascular death, nonfatal myocardial infarction, heart failure or stroke) on long-term follow-up among women being evaluated for ischaemic heart disease, according to a study. Moreover, this risk is mainly driven by a more than twofold rise in stroke risk.
2 days ago
Cardiac rehabilitation (CR) decreases mortality and may improve health-related quality of life (HRQOL), a new meta-analysis of recent observational studies shows. However, because of contradictions from recent clinical trials, further studies are needed to fully assess the relevance of current CR programmes.
Special Reports
25 May 2017
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
07 Mar 2017
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
16 Feb 2017
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
16 Dec 2016
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 12 Dec 2016
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Pearl Toh, 07 Dec 2016
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
Conference Reports
Elvira Manzano, 05 Apr 2017
Treatment with sodium- glucose cotransporter 2 (SGLT-2) inhibitors reduces the risk of hospitalization for heart failure (hHF) and death compared with other glucose-lowering drugs, the retrospective, observational CVD-REAL* study has shown.
Elvira Manzano, 31 Mar 2017
Adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to statin therapy to further lower bad cholesterol does not cause memory loss or other cognitive issues in patients with known cardiovascular disease (CVD), the EBBINGHAUS* trial has shown, giving clinicians some sense of reassurance.
Pearl Toh, 30 Mar 2017
The everolimus-eluting bioresorbable vascular scaffold (BVS), Absorb, was noninferior to Xience metal stent for target lesion failure (TLF) by 1 year and between 1–2 years, but was associated with significantly higher cumulative TLF rates by 25 months, according to the ABSORB III trial presented at the ACC.17 in Washington, DC, US.
Roshini Claire Anthony, 28 Mar 2017

The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.

Pearl Toh, 28 Mar 2017
Transcatheter aortic valve replacement (TAVR) is an effective and safe alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients in the real world, with no significant difference in stroke and mortality rates at 1 year, and discharge to home being more common among TAVR patients, according to the ADVICE* study presented at the recent ACC.17 Scientific Session held in Washington, DC, US.
Elaine Soliven, 28 Mar 2017

Noninvasive magnetic resonance (MR) perfusion imaging may be effective as initial guided management in patients with stable angina and intermediate-to-high risk for coronary artery disease (CAD) compared with invasive angiography and fractional flow reserve (FFR), according to the MR-INFORM* trial presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) held in Washington, DC, US.

28 Mar 2017
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!